The US Food and Drug Administration (FDA) has approved inclisiran (Leqvio) as an adjunct to statins for further reduction of LDL cholesterol levels, the drug's developer, Novartis, announced today.
The British Medical Association (BMA) and the Royal College of General Practitioners (RCGP) are raising concerns about the use and planned rollout of the LDL cholesterol-lowering medication inclisiran ...
Cholesterol bloodstream Inclisiran is a chemically synthesized small interfering RNA that targets proprotein convertase subtilisin-kexin type 9 (PCSK9) messenger RNA. A Complete Response Letter (CRL) ...
GP practices are ‘under no obligation’ to prescribe cholesterol-lowering injection inclisiran without a local enhanced service (LES), local leaders have stressed. LMCs across the country have reminded ...
New York, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Inclisiran - Emerging Insight and Market Forecast - 2030" - https ...
The US Food and Drug Administration (FDA) issued a complete response letter regarding Novartis' new drug application (NDA) for inclisiran, a novel treatment for elevated low-density lipoprotein ...
Inclisiran is a chemically synthesized small interfering RNA that targets proprotein convertase subtilisin-kexin type 9 (PCSK9) messenger RNA. Findings from a pooled post-hoc analysis of three phase 3 ...
Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal ...
Please provide your email address to receive an email when new articles are posted on . A pooled analysis of three phase 3 trials assessing inclisiran found that the agent safely lowered LDL in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback